The race to restore sight

Overview

Stanford researchers implanted a chip smaller than a Tic Tac under the retinas of 38 blind patients. A year later, 27 could read again, including some who read entire books. The PRIMA device, published October 20, 2025 in the New England Journal of Medicine, is the first prosthetic to restore functional vision to people with macular degeneration—the leading cause of irreversible blindness.

Three competing approaches are racing to cure blindness: retinal implants that replace dead photoreceptors, optogenetic gene therapies that reprogram surviving neurons, and cortical brain chips that bypass the eye entirely. The stakes are massive—over 5 million people worldwide have geographic atrophy from macular degeneration, and the broader market for vision restoration could hit $7 billion by 2032. But the field is littered with failures: the pioneering Argus II implant went obsolete in 2020, and 350 patients have unsupported devices embedded in their eyes.

Play on this story Voices Debate Who Said What? Predict

Key Indicators

27 of 32

Patients regained reading ability

PRIMA trial participants who could read after one year with the implant

5 lines

Average vision improvement

Mean visual acuity gain on eye charts; one patient improved 12 lines

5 million

People with geographic atrophy

Global population suffering vision loss from advanced macular degeneration

$7B

Projected market by 2032

Artificial retina implant market forecast, growing at 21% annually

20/42

Best-case vision with zoom

Equivalent visual acuity achieved by some PRIMA patients using digital enhancements

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play

Timeline Five events from this story — drag them oldest to newest. Log in to play

Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Daniel Palanker

Co-senior author of landmark PRIMA clinical trial

José-Alain Sahel

Co-senior author and vision restoration pioneer

Max Hodak

Former Neuralink president, leading PRIMA commercialization

Elon Musk

Developing competing cortical vision implant called Blindsight

Organizations Involved

Science Corporation

Neurotechnology Company

Commercializing PRIMA retinal implant system

Four-year-old neurotechnology company that acquired Stanford's PRIMA technology and raised $260 million to commercialize it.

Stanford Medicine

Academic Medical Center

Developed PRIMA technology, co-led clinical trials

Stanford's Department of Ophthalmology developed the photovoltaic retinal prosthesis technology underlying PRIMA.

Neuralink

Neurotechnology Company

Developing Blindsight cortical visual prosthesis, FDA breakthrough designation received

Brain-computer interface company developing Blindsight, a cortical implant that bypasses the eye to restore vision.

Second Sight Medical Products

Medical Device Company (defunct operations)

Pioneered Argus II retinal implant, ceased operations 2020, merged 2023

Developed the first FDA-approved retinal prosthesis but ceased support, stranding 350 implanted patients.

GenSight Biologics

Gene Therapy Company

Conducting PIONEER trial of GS030 optogenetic therapy

Developing optogenetic gene therapy that reprograms surviving retinal neurons to become light-sensitive.

Timeline

January 2002 October 2025

11 events Latest: October 20th, 2025 · 7 months ago Showing 8 of 11

Tap a bar to jump to that date

October 2025
PRIMA Restores Reading Vision in Blind Patients
Latest Research

New England Journal of Medicine publishes landmark PRIMA trial: 27 of 32 patients regained reading ability after one year with implant.
October 20th, 2025
September 2024
Neuralink's Blindsight Gets FDA Fast-Track
Regulatory

FDA grants breakthrough device designation to Neuralink's Blindsight cortical visual prosthesis, accelerating development timeline.
September 1st, 2024
February 2023
GenSight Reports Optogenetics Trial Data
Research

GenSight Biologics announces 1-year safety and efficacy signals from PIONEER trial of GS030 optogenetic therapy for retinitis pigmentosa.
February 1st, 2023
May 2021
Hodak Leaves Neuralink, Founds Science Corp
Market

Neuralink co-founder and president Max Hodak departs to launch Science Corporation, targeting vision restoration with retinal implants.
May 1st, 2021
January 2021
First Optogenetic Vision Restoration
Research

Sahel's team achieves first partial vision restoration in blind patient using optogenetic gene therapy with ChrimsonR protein.
January 1st, 2021
April 2020
PRIMA Early Safety Data Published
Research

Palanker and Sahel publish preliminary PRIMA safety data in Nature Communications, showing feasibility of photovoltaic subretinal prosthesis.
April 1st, 2020
January 2020
Argus II Support Ends, Devices Go Obsolete
Market

Second Sight ceases technical support for Argus II and Orion implants, stranding patients with obsolete devices still embedded in eyes.
January 1st, 2020
May 2019
Second Sight Halts Argus II Manufacturing
Market

Revenue shortfalls force Second Sight to stop manufacturing Argus II despite 350 patients worldwide with implanted devices.
May 1st, 2019
February 2013
FDA Approves First Retinal Implant
Regulatory

Argus II receives FDA approval under humanitarian device exemption, becoming first approved visual prosthesis in the United States.
February 13th, 2013
January 2005
Palanker Conceives Photovoltaic Retinal Prosthesis
Research

Daniel Palanker at Stanford realizes the eye's transparency enables wireless information delivery via infrared light, conceiving PRIMA.
January 1st, 2005
January 2002
First Human Retinal Prosthetic Implant
Milestone

Second Sight's Argus I device implanted in first six patients with retinitis pigmentosa, launching the modern era of visual prosthetics.
January 1st, 2002

#timeline [x-show="expanded"] { display: revert !important; opacity: 1 !important; } #timeline .timeline-toggle-btn { display: none; }

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1984-present

Cochlear Implants Transform Hearing Restoration

The FDA approved the first cochlear implant in 1984 to replace the sense of hearing in profoundly deaf adults. Early devices provided limited speech recognition, and many in the deaf community opposed them. But successive generations improved dramatically. Today over 1 million people worldwide have cochlear implants, with many users achieving near-normal hearing and speech comprehension.

Then

Initial skepticism and modest results gave way to steady technological refinement and expanding FDA indications through the 1990s-2000s.

Now

Cochlear implants became standard of care for profound deafness, proving that prosthetic sensory restoration was medically and commercially viable at scale.

Why this matters now

Cochlear implants provide the template for visual prosthetics: early modest results, iterative improvement, eventual mainstream acceptance, and a sustainable market supporting long-term device improvements.

2013-2020

Argus II Goes Obsolete, Stranding Implanted Patients

Second Sight's Argus II became the first FDA-approved retinal prosthesis in 2013. More than 350 blind patients worldwide paid $150,000 each for the implant. But the company generated only $32 million in revenue against $300 million invested. Financial pressures from COVID-19 forced Second Sight to cease manufacturing in 2019 and stop technical support in 2020, leaving patients with obsolete devices still embedded in their eyes. A 2023 merger promised renewed support but highlighted devastating ethical failures.

Then

Patients lost the ability to use their implants as external hardware failed and software support vanished, some describing it as 'going blind twice.'

Now

The Argus II collapse became a cautionary tale driving regulatory focus on device longevity and company obligations to support implanted patients throughout their lifetimes.

Why this matters now

The Argus II failure hangs over every new visual prosthetic, raising critical questions about whether companies like Science Corp can sustain long-term patient support if commercial success proves elusive.

1990-2003

Human Genome Project Accelerates Medical Technology

The Human Genome Project sequenced all human DNA, taking 13 years and costing $2.7 billion. The achievement seemed like a moonshot with unclear applications. But it catalyzed an explosion in genomics, gene therapy, and precision medicine. Tools that once took years and millions became routine in labs worldwide within a decade. Gene therapies for previously untreatable conditions began reaching patients in the 2010s-2020s.

Then

The completed genome initially underwhelmed—no immediate cures emerged, and many questioned the investment's value through the early 2000s.

Now

The genome project's tools and knowledge enabled an entire generation of therapies including CAR-T cancer treatments, gene therapies for blindness, and mRNA vaccine platforms.

Why this matters now

Vision restoration technologies like optogenetics and retinal prosthetics directly descend from genomics and neuroscience breakthroughs the Human Genome Project accelerated, showing how foundational research enables seemingly impossible medical achievements.